Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 10—October 2010

Research

Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

Scott K. HeysellComments to Author , Jane L. Moore, Suzanne J. Keller, and Eric R. Houpt
Author affiliations: Author affiliations: University of Virginia, Charlottesville, Virginia, USA (S.K. Heysell, E.R. Houpt); Virginia Department of Health, Richmond, Virginia, USA (J.L. Moore, S.J. Keller)

Main Article

Table 2

Comparison of median serum concentration at 2 hours after medication administration as estimate of peak serum concentration levels and expected range, therapeutic drug monitoring, Virginia, USA, March 1, 2007–May 1, 2009*

Medication Median serum concentration, µg/mL (IQR) Expected serum concentration range, µg/mL
Isoniazid
Daily 1.9 (1.1–3.5) 3–6
Biweekly
9.8 (2.8–11.2)
9–18
Rifampin daily and/or biweekly
7.4 (2.5–11.4)
8–24
Ethambutol†
2.5 (1.7–3.2)
2–6
Pyrazinamide† 28.1 (26.5–33.2) 20–50

*IQR, interquartile range.
†All patients with therapeutic drug monitoring levels obtained for ethambutol and pyrazinamide were taking weight-based daily doses of these medications.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO